



NextGen...a Contract Sales Force for Innovative CRO's

NextGen Pharma Technologies, Inc. is a "Contract Sales Organization" representing a number of unique CROs. NextGen provides discovery and development solutions by matching the needs of pharma and biotech clients with pre-qualified niche service providers. NextGen CROs have solid reputations for being 'user friendly' collaborative, responsive, innovative and providing shorter lead and turn around times than some of the larger CROs. An overview of the companies represented is provided below and on our website at www.nextgenpharma.com.

CanCog Technologies, Inc., of Toronto, Canada, provides predictive behavioral and cognitive studies to evaluate therapeutic drug and nutritional effects in several proprietary models. CanCog's has a state of the art facility for housing dogs and cats and provides natural non-invasive models for examining therapeutics efficacy support across the CNS area to increase intellectual property value and strategize effective clinical trials. Areas of specialization include: Alzheimer's disease, and mild cognitive impairment; anxiety, learning and memory; behavioral/cognitive safety; eating disorders and obesity; arthritis; and epilepsy. CanCog's specialized services include: non-invasive behavioral assessment; DEXA scanning; imaging (MRI, SPECT, PET); glucose tolerance and insulin sensitivity; and blood collection. CanCog also provides a wide spectrum of rodent based models focusing on therapeutic evaluation. www.cancog.com

CoreRx Pharmaceuticals, of Tampa, FL, provides a comprehensive CMC program for virtually all Pharmaceutical and Biotechnology dosage forms. Services include: Pre-Formulation and Formulation Development; and Analytical and Stability Development and Support. Clinical Manufacturing, Packaging and Labeling are performed in their 10,000 square foot state of the art GMP process facility. The founding management team brings decades of large CRO and Pharma experience to the company. CoreRx mission is to provide value-added innovative solutions within budget and timelines, and in compliance with current GMP and ICH guidelines. www.corerxpharma.com

Custom Biologics, of Mississauga, Ontario, Canada, specializes in the development and validation of bioanalytical and biological assays to support innovative drug development programs. Their service areas include, bioanalytical LC-MS/MS (large and small molecule), ligand-binding assays, flow cytometry, cell culture based assays, protein analytical mass spectrometry and anti-drug antibody/neutralizing assays. All projects are conducted in a GLP environment fully compliant with FDA guidelines, 21 CFR Part 58. Their thorough understanding of complex scientific and regulatory issues associated with the development and validation of biological and bioanalytical assays adds value to their client's drug development programs. www.custombiologics.com

Melior Discovery, Inc., of Exton, PA, is a pioneer of high-throughput *in vivo* pharmacology applied to drug discovery and development. The company has developed a unique technology platform, *theraTRACE*[®], that is used by pharmaceutical partners for drug profiling and repositioning generally, and the identification of new therapeutic indications specifically. The Company also leveraged these core competences to provide high quality, cost effective *in vivo* pharmacology services including a broad suite of specialized disease models representing Obesity, Psychotherapeutic, Sleep/Wake, Inflammation/Immunology, Gastrointestinal, Urogenital, Diabetes, Pain, Neurodegeneration, Cardiovascular, Dermatology, and Allergy/Respiratory therapeutic areas. Melior's rodent PK models range from a rapid PK screening service to multi-group custom PK study designs that are integral to the interpretation of drug properties and the ability to relate these to optimum dosing paradigms. Melior uses state-of-the-art high-throughput LC/MS/MS equipment in their bioanalytical lab to offer the most sensitive bioanalytical method possible. www.meliordiscovery.com

MuriGenics, Inc., of Mare Island, Vallejo, CA, provides both *in vivo* and *in vitro* preclinical services. They specialize in validated phenotypic mouse and rat models in five major therapeutic areas: Autoimmune Diseases, Cancer (Xenografts), Cardiovascular, Diabetes/Metabolic Disorders, and Inflammation (Arthritis). Additionally, MuriGenics conducts non-GLP Chronic Toxicology and PK/TK studies. Their *in vitro* capabilities include: Cell Based Assays (FACS, Ca⁺⁺ Mobilization, Cell Proliferation, and Apoptosis), Monoclonal Antibody Production, Antibody Characterization, and Luminex Multianalyte Assays (Protein and bDNA). www.murigenics.com

NoAb BioDiscoveries, Inc. (NoAb), of Ontario, Canada, provides comprehensive non-GLP Discovery DMPK services. The primary focus at NoAb is *in vivo* PK studies using advanced surgical models and *in vitro* ADMET testing, for Lead Candidate Optimization (LCO). *In vivo* PK studies with serial sample collection are conducted in cannulated mice, rats, hamsters, and guinea pigs. NoAb also offers serial cerebrospinal fluid collection as well as intracerebral microdialysis in freely moving rats, to investigate BBB penetration. The *in vitro* ADMET program includes cell permeability, plasma protein binding, activity and gene expression based Cytochrome P450 inhibition and induction studies, Pgp, metabolic stability, and cytotoxicity studies. Bioanalytical services including metabolite profiling utilizing LC-MS/MS are also offered. In addition, NoAb provides gene expression analysis using DTE[™]: a proprietary microarray-based technology that allows investigators to simultaneously survey the gene expression levels of over 140 ADME associated genes. www.noabbiobiodiscoveries.com

PhoenixBio, of Hiroshima, Japan, are the producers of the PXB-mouse. PXB-mice are Chimeric mice with a healthy and functional liver that has been 70 to 90 percent repopulated by human hepatocytes. PhoenixBio produces them by transplanting human hepatocytes to immunodeficient mice that have liver disease (uPA/SCID). PXB-mice exhibit normal histological structures in the liver and secrete human Albumin making them an excellent animal model for PK studies. PhoenixBio has the ability to run study services requiring the use of radioisotopes, or to be performed in compliance with the GLP-standard at the research facilities of their strategic partner making PXB-mice an excellent candidate for Metabolism with Radioactivity studies. The expression and activity of human metabolic enzymes and transporters, and the secretion of human type bile acids in PXB-mouse liver has been scientifically confirmed and the PXB-mice have also been successfully infected with hepatitis B and C viruses. <http://phoenixbio.co.jp/en>.

Pre-Clinical Research Services, Inc. (PCRS), of Fort Collins, CO, is a pre-clinical contract research organization. Founding member, Don Maul, DVM, MS, ACLAM, and staff have provided contract pre-clinical testing services for the pharmaceutical and medical device industries for over 15 years. They operate out of a 22,000 sq. ft. vivarium, which includes a state-of-the-art surgical suite. The pre-clinical services include: PK studies including direct duodenal dosing in dogs and pig dermal absorption PK; Experimental surgery (dog osteoarthritis, biomaterial implants, orthopedic, and cardiovascular models); Evaluation of the dog osteoarthritis model which is enhanced by gait analysis using a Kistler force plate along with imaging capabilities including MRI, CT scan and digital X-ray imaging; Pig DTH dermal hypersensitivity model; Ocular studies in dogs, rabbits and rats; Toxicology; Animal model development; Conference facilities are available for groups of up to 50 people for hosting surgeon training programs; Species include dogs, pigs, sheep, rats, mice, hamsters, guinea pigs, rabbits and cats. www.preclinicalresearch.com

Xenometrics, LLC, of Stilwell, KS, is a FDA GLP compliant, USDA registered, AAALAC accredited contract research organization, providing preclinical study services to the pharmaceutical and biotech industry. Xenometrics' 78,000 sq. ft. dedicated vivarium space includes capacity for rodents, dogs, nonhuman primates, rabbits, guinea pigs, and minipigs. Xenometrics' study services include: DMPK Studies (including radio-labeled studies), General Toxicology Studies, Safety Pharmacology Studies, and Development & Reproductive Toxicology Studies. Xenometrics' scientific staff represent a wealth of experience, and have assisted hundreds of clients with their research and development needs; from early stage research, to IND enabling studies, and further preclinical safety studies to support our clients' clinical development programs. www.xenometricsllc.com



FOR MORE INFORMATION CONTACT:

Eastern Region
Layne Los, PhD
719-213-7280 (Cell)
Layne@nextgenpharma.com

Western Region
Gary Tye
719-337-9550 (Cell)
gvttye@nextgenpharm.com

Rocky Mtn. Region
Cheryl Hite
970-222-3844 (Cell)
Cheryl@nextgenpharma.com

1235 Lake Plaza Drive, Suite 134, Colorado Springs, CO 80906
Phone: 719-540-2888 Fax: 719-540-5003

Visit our website: www.NextGenPharma.com